The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies.

The datapack covers wealth of financial...

In fact, a new Forbes survey finds that the cost of meds targeted to small groups of patients with serious genetic disorders dwarfs the prices of...

in Cheshire saw fourth-quarter earnings climb more than 17-fold from a year earlier, propelled largely by a one-time tax benefit stemming from development of its treatment for a rare blood disorder.

The developer and marketer of...

said Thursday its fourth-quarter profit surged on a hefty tax benefit and sales of the blood disorder treatment Soliris, its only marketed product.

Including a tax gain of $214.5 million, the company earned $237.1 million, or $2...

Alexion Pharmaceuticals Inc.

said Thursday its fourth-quarter profit surged on a hefty tax benefit and sales of the blood disorder treatment Soliris, its only marketed product.

Including a tax gain of $214.5 million, the company earned ...

CHESHIRE, Conn.

-- (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc.

(NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2009.

For the three...

(NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2009.

For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc.

("Alexion" or,...

(NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2009.

For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc.

('Alexion' or, the 'Company') reported net product...

(NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2009.

For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc.

("Alexion" or, the "Company") reported net product...